NEW YORK (GenomeWeb News) - American Type Culture Collection will use certain genomic technologies to study pancreatic tissue samples collected at a New Jersey Hospital for biomolecules that can be used to help detect, monitor, and potentially treat pancreatic cancer, ATCC said Thursday.
ATCC’s platform consists of integrated genomics, proteomics, and bioinformatics technologies and “has already demonstrated effectiveness in uncovering novel biomarkers for type 2 diabetes,” the company said.
Under the agreement, ATCC will use its biomarker-discovery platform on pancreatic cancer samples from The Valley Hospital of Ridgewood, and the hospital will provide blood and clinical advice on validation and application of biomarker discoveries stemming from the collaboration.
ATCC scientists will also use the company’s Cell Biology Collection to test for the presence or absence of “various biomarkers across a wide range of cell lines.” ATCC and The Valley Hospital will form a Joint Research and Development Committee to address the objectives and progress of the research initiatives.
Financial terms of the agreement were not released.